Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients.

Purpose: Non-invasive monitoring of circulating tumor DNA (ctDNA) has the potential to be a readily available measure for early prediction of clinical response. Here, we report on early ctDNA changes of KRAS G12C in a Phase 2 trial of adagrasib in patients with advanced, KRAS G12C-mutant lung cancer.

Experimental Design: We performed serial droplet digital PCR (ddPCR) and plasma NGS on 60 KRAS G12C-mutant patients with lung cancer that participated in cohort A of the KRYSTAL-1 clinical trial.

[The beauty perspective of the horizontal lip position].

The purpose of the present study was to explore the role of horizontal lip position in the evaluation of beauty in a lateral facial profile. The sample size of 1,000 students were randomly selected from all the Junior High Schools in the city of Taipei. One hundred and ten 12-year-old students were judged to be good looking and were selected by 7 panelists of different educational backgrounds.